Navigate Up
Sign In


MSD welcomes new apprentices: In August, two young people take on their professional training as Laboratory Technicians EFZ (which will lead to a Certificate by the Swiss Confederation) in biology at Werthenstein BioPharma GmbH in Schachen and another school graduate will start his apprenticeship as a Business Administrator EFZ at MSD Merck Sharp & Dohme AG in Lucerne. With that, MSD is offering a total of eight recruits the opportunity of an apprenticeship in Switzerland.

Viral Hepatitis - the "Hepatitis Strategy Switzerland" network is actively informing. In connection with this year's world hepatitis day, the "Hepatitis Strategy Switzerland" network is informing more intensely about the liver disease that is caused by a viral infection. This reason for this: Viral hepatitis is more widespread than commonly supposed.
Read more.

As a signatory to Switzerland’s Pharma Cooperation Code (PCC) and starting in 2016, MSD will disclose annually the transfers of value provided to healthcare professionals and organisations in the prior year.MSD supports the PCC and the efforts to increase transparency and thus strengthen the trust in interactions and collaboration between the pharmaceutical industry and healthcare providers. The overview of the transfers of value provided by MSD in 2015 is available here.

​MSD in Switzerland

MSD is one of the world's leading healthcare companies, with its headquarters in the USA (Merck & Co., Inc., Kenilworth, NJ, USA). In Switzerland, MSD is one of the most important pharmaceutical research companies. From our base at Lucerne we serve the Swiss healthcare market and support more than 70 subsidiaries across Europe, Canada, the Middle East, Africa, Brazil, India, and China. Welcome to MSD.

MSD as an employer 
To achieve our ambitious goals, we need the best possible specialist staff and highly committed employees. We offer various positions in a wide range of business areas like for example within our local and international sales organizations, research & development, manufacturing, and within the core departments of our global business located in Lucerne.
Find out more​

​The Antibiotics Challenge  

For more than 70 years, MSD has contributed to the discovery and development of novel medicines to combat infectious diseases. The combination with the bio-pharmaceutical company Cubist in January 2015 is an important milestone in this respect to intensify research in view of an increasing resistance against antibiotics – one of the biggest global health challenges - and develop innovative medicines for patients with potentially life-threatening infections diseases caused by bacteria. Cubist’s deep expertise and compelling portfolio and pipeline complement our broad portfolio of Hospital Acute Care. This will help advance a pipeline of candidates that hold the potential for making a meaningful difference in the lives of patients around the world.

General Remark:
Please be aware of the fact that each time when using one of the links in this website, you are leaving the Merck Sharp & Dohme AG, Switzerland (MSD), website and thus our sphere of responsibility. The linked Internet pages have their own terms of use and may be subject to different laws and standards.